Zacks Research Has Bearish Estimate for Revvity Q3 Earnings

Revvity Inc. (NYSE:RVTY) – Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for Revvity in a report released on Thursday, June 25th. Zacks Research analyst Team now forecasts that the company will earn $1.30 per share for the quarter, down from their previous forecast of $1.33. The consensus estimate for Revvity’s current full-year earnings is $5.25 per share. Zacks Research also issued estimates for Revvity’s Q1 2027 earnings at $1.16 EPS, Q3 2027 earnings at $1.44 EPS and FY2027 earnings at $5.78 EPS.

Revvity (NYSE:RVTY) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The company had revenue of $711.12 million during the quarter, compared to the consensus estimate of $704.07 million. During the same quarter in the prior year, the firm earned $1.01 EPS. Revvity’s quarterly revenue was up 7.0% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS.

Other research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Weiss Ratings raised Revvity from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday. Stifel Nicolaus dropped their target price on Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a research report on Wednesday, May 6th. Wolfe Research started coverage on Revvity in a research note on Tuesday, June 2nd. They set a “peer perform” rating for the company. Finally, TD Cowen raised their price target on Revvity from $115.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Revvity presently has an average rating of “Hold” and an average target price of $108.33.

Revvity Stock Down 0.0%

Shares of NYSE:RVTY opened at $112.98 on Monday. Revvity has a fifty-two week low of $81.22 and a fifty-two week high of $118.30. The company has a quick ratio of 1.41, a current ratio of 1.72 and a debt-to-equity ratio of 0.37. The firm’s 50-day simple moving average is $97.46 and its 200-day simple moving average is $97.74. The company has a market cap of $12.60 billion, a price-to-earnings ratio of 54.06, a PEG ratio of 2.47 and a beta of 1.11.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RVTY. Ascentis Independent Advisors purchased a new position in Revvity in the first quarter valued at about $29,000. CYBER HORNET ETFs LLC purchased a new stake in shares of Revvity during the 2nd quarter worth approximately $32,000. Cromwell Holdings LLC boosted its stake in shares of Revvity by 141.4% during the 4th quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after acquiring an additional 198 shares in the last quarter. MUFG Securities EMEA plc acquired a new stake in shares of Revvity in the 2nd quarter worth approximately $34,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Revvity in the 2nd quarter worth approximately $49,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Friday, July 17th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, July 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. Revvity’s payout ratio is currently 13.40%.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.